ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1820

Prevalence and Risk-Factors for Asymptomatic Coronary-Artery Calcifications in Young Patients with Systemic Lupus Erythematosus

Juanita Romero-Diaz1, Rocio Moran-Contla2, Eric Kimura-Hayama3, Sergio Criales-Vera3, Carlos Núñez-Álvarez2, Roberto Ivan Acosta-Hernandez4, Mario César Ocampo-Torres5 and Jorge Sánchez-Guerrero6, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, 2Instituto Nacional de Cs Medicas y Nutricion Salvador Zubiran, Mexico city, Mexico, 3Radiology Department, Instituto Nacional de Cardiologia, Mexico City, Mexico, 4Society for Worldwide Med Exchange, North Bay Village, FL, 5Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 6Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: atherosclerosis and risk assessment, Lupus

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Premature atherosclerosis is a major cause of morbidity and mortality in females with systemic lupus erythematosus (SLE), but little is known about the frequency, extent, and risk-factors of coronary-artery calcifications (CAC) in young patients with SLE.

Methods:

We studied 223 SLE patients (95 males and 128 females) attending our outpatient clinic and 193 healthy subjects (100 males, 93 females) w/o preexisting coronary heart disease, matched by age and race. Patients and controls had a standardized assessment of demographic characteristics and traditional cardiovascular risk factors. In addition, lupus patients had an evaluation of lupus characteristics, medications, and laboratory tests including immunological, extended lipid profile, homocystein, and hsCRP. All patients and healthy controls were screened for coronary-artery calcifications using a 64-slice Multidetector Computed Tomography and the extent of calcification was measured by means of the Agatson score.

Results:

Mean (SD) age of lupus patients and controls was 32.9 (9.4) and 33.5 (9.8) years, respectively. Coronary-calcifications were detected in 25 patients (11%) and 7 (4%) controls (OR 3.35, 95% CI 1.36-9.38, p=0.004). Median calcium score in patients was 15.9 (0.2-576.8), and 7.7 (1.1-140.2) in controls. Calcifications in lupus patients and controls were detected since age 32 and 41 years, respectively. In two patients, calcifications were detected within 3 years of diagnosis. The multivariate analysis showed that age (OR 1.13, 95% CI 1.08 – 1.18), smoking (OR 3.50 95% CI 1.32 – 9.27), male gender (OR 2.62 95% CI 1.04 – 6.57), and SLE diagnosis (OR 4.41 95% CI 1.64 – 11.85) were associated with CAC in the whole population.

Among the lupus patients, those with calcifications were older (42.1 + 8.6 vs 31.8 + 8.9 years, P<0.001), males (68% vs 39%, P=0.006), waist (91.4 + 14.2 vs 85.6 + 12.7 cm, P=0.02), current smoking (32% vs 10%, P=0.006), hypertension (48% vs 28%, P=0.04), homocysteine levels (17.1 + 14.8 vs 11.7 + 6.4, P=0.009), Framingham risk score [5(1-25) vs 1(1-13), P<0.001], MetS (44% vs 15% , P=0.001].  Lupus duration was longer (11.1 + 8.9 vs 5.8 + 4.3 years, P=0.006), and cumulative dose of prednisone higher [61.7(0.24-454.2) vs 49.9(8.5-106.5) grams, P=0.001] in comparison to patients with no calcifications. No difference was observed in lupus manifestations, clinical activity during the course of the disease, autoantibodies, and use of anti-malarials and aspirin. Logistic regression adjusting by disease duration showed an independent association of age (OR 1.12, 95% CI 1.05-1.16, p= P<0.001), smoking (OR 3.69, 95% CI 1.04-13.1, p=0.04) and cumulative dose of prednisone (OR 1.03, 95% CI 1.005-1.06, p=0.02) with calcifications.

Conclusion:

Asymptomatic coronary-artery calcifications are more common, extensive, and present at younger age in SLE patients than in the controls. Their association, principally to traditional risk-factors than lupus characteristics, raise the possibility of modifying their burden.


Disclosure: J. Romero-Diaz, None; R. Moran-Contla, None; E. Kimura-Hayama, None; S. Criales-Vera, None; C. Núñez-Álvarez, None; R. I. Acosta-Hernandez, None; M. C. Ocampo-Torres, None; J. Sánchez-Guerrero, None.

To cite this abstract in AMA style:

Romero-Diaz J, Moran-Contla R, Kimura-Hayama E, Criales-Vera S, Núñez-Álvarez C, Acosta-Hernandez RI, Ocampo-Torres MC, Sánchez-Guerrero J. Prevalence and Risk-Factors for Asymptomatic Coronary-Artery Calcifications in Young Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/prevalence-and-risk-factors-for-asymptomatic-coronary-artery-calcifications-in-young-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-risk-factors-for-asymptomatic-coronary-artery-calcifications-in-young-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology